← Leaderboards
Beatriz M. Carreno
Washington University
$3,376,000
Attributed
$8,045,357
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,045,357 · 4
By mechanism
R01$2,730,478 · 1
UG3$2,717,473 · 1
UH3$2,238,704 · 1
R21$358,702 · 1
Top collaborators
- Gerald P Linette8 shared
- Carl H. June3 shared
Most similar at Washington University
Same institution · by research overlap
- Lilianna Solnica-Krezel$20,466,821
- Christine T Pham$10,070,288
- Vineet Gupta$8,266,585
- Sean P. J. Whelan$36,954,740
- Jeffrey Robert Millman$5,406,210
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsUniversitiesGenomicsMissense MutationTumorTumor AntigensT-LymphocyteNext GenerationImmuneAllelesMutateMutantResponseMalignant Neoplasm Of LungVariantEnsureCancer PatientProteomicsLaboratoriesImmune TargetingMelanomaAlgorithmsCancer GenomeAntigen Targeting
Grant awards (10)
Next generation T cell therapies for mutant KRAS solid tumors$2,238,704
UH3 · FY2025 · CA · contact PI
Next generation T cell therapies for mutant KRAS solid tumors$1,412,213
UG3 · FY2024 · CA · contact PI
Next generation T cell therapies for mutant KRAS solid tumors$1,305,260
UG3 · FY2023 · CA · contact PI
Integrated Discovery Pipeline for Tumor Neoantigens$541,899
R01 · FY2020 · CA · contact PI
Integrated Discovery Pipeline for Tumor Neoantigens$530,736
R01 · FY2019 · CA · contact PI
Integrated Discovery Pipeline for Tumor Neoantigens$552,250
R01 · FY2018 · CA · contact PI
Integrated Discovery Pipeline for Tumor Neoantigens$542,768
R01 · FY2017 · CA · contact PI
Integrated Discovery Pipeline for Tumor Neoantigens$562,825
R01 · FY2016 · CA · contact PI
SOMATIC NON-SYNONYMOUS MUTATIONS AS UNIQUE TUMOR ANTIGENS IN MELANOMA$160,342
R21 · FY2014 · CA · contact PI
SOMATIC NON-SYNONYMOUS MUTATIONS AS UNIQUE TUMOR ANTIGENS IN MELANOMA$198,360
R21 · FY2013 · CA · contact PI